Friday, May 16, 2014
Swiss Venture Capital report for 2013
Probably old new by now, but interesting is the Swiss Venture Capital Report for 2013.
Sunday, May 11, 2014
Covagen with Conjugated antibodies
Well, it's been a while since I've written about Covagen, and I see they have two conjugations of antibodies with Fynomers (FynomAbs) in clinical trials already, and it looks like this is with their partner Mitsubishi Tanabe Pharma Corp.
The conjugation makes sense, the molecular weight of the Fynomers would probably mean they don't around long enough in the body to be clinical useful, but an antibody conjugate can take advantage of the bodies antibody recycling systems and thus stick around longer. This is probably also an approach that will be strongly considered by the other alternative scaffold company Molecular Partners (and yes indeed, here are their notes only they are selling DARPins as a tag to increase the half-life of other molecules by targeting the DARPin to serum proteins or as fusion proteins).
I wonder if Fynomers will show up as a drug on its own, without the antibody conjugation. That is the promise after all of alternative scaffolds, antibody-like specificity but cheaper and easier to make. Right now the most successful approach appears to be making bispecific antibodies.
The conjugation makes sense, the molecular weight of the Fynomers would probably mean they don't around long enough in the body to be clinical useful, but an antibody conjugate can take advantage of the bodies antibody recycling systems and thus stick around longer. This is probably also an approach that will be strongly considered by the other alternative scaffold company Molecular Partners (and yes indeed, here are their notes only they are selling DARPins as a tag to increase the half-life of other molecules by targeting the DARPin to serum proteins or as fusion proteins).
I wonder if Fynomers will show up as a drug on its own, without the antibody conjugation. That is the promise after all of alternative scaffolds, antibody-like specificity but cheaper and easier to make. Right now the most successful approach appears to be making bispecific antibodies.
Subscribe to:
Posts (Atom)